Protein-Protein Interactions 2019 #PPIs19

4 April 2019 10:00 - 5 April 2019 16:15, Leeds, United Kingdom

Follow us on Twitter:  #PPIs19

Virtually all vital cellular processes are controlled by protein-protein interactions (PPIs), including gene expression, proliferation, intracellular communication and apoptosis. The understanding and manipulation of PPIs therefore plays an important role in fathoming the biology of healthy and diseased states. Achieving this goal will lead to new probes of cell signalling pathways or systems biology, and molecular therapeutics for addressing unmet medical need.

To date, only a few PPIs have been the subject of drug discovery initiatives by the pharmaceuticals industry. Given the potential opportunities around modulating more of the estimated >650,000 PPIs, this field continues to generate considerable scientific interest, which has stimulated significant academic and industrial innovation. This meeting will address recent advances in the area. Topics will include: inducing protein degradation using small molecules, protein engineering and synthetic biology, integration of computational and experimental methods to study PPIs, characterisation and identification of new PPI inhibitors and lead optimization challenges for molecules targeting PPIs from case studies in drug discovery.Speakers from both industry and academia will describe strategies for addressing these challenges whilst showcasing the opportunity for creativity and innovation.

Delegate Fees

GB£220 . . . . . . . . . . . . . . . . . SCI/RSC Member
GB£290.. . . . . . . . . . . . . . . . . Non-Member 
GB£85 . . . . . . . . . . . . . . . . . . SCI/RSC Student Member
GB£135 . . . . . . . . . . . . . . . . . SCI Subsidised Member


Thursday 4 April

10.00 Registration

10.20 Introductory remarks

10.30 Plenary Talk: Structure based design of high affinity inhibitors of B-cell lymphoma 6 (BCL6) protein-protein interaction
Dr Graeme Robb, AstraZeneca

11.15 Preclinical validation of a therapeutic peptide targeting a protein/protein interaction
Dr Angelita Rebollo, Centre d’Immunologie et des Maladies Infectieuses

11.45 Designing and disrupting protein-protein interactions in test tubes and cells
Professor Dek Woolfson, University of Bristol

12.15 Lunch, exhibition and posters

13.30 Mimicking Protein-Protein Interactions in Persistent Bacteria
Dr Anna Barnard, Imperial College

13.45 Platforms for the generation and high-throughput screening of cyclic peptide libraries
Professor Ali Tavassoli, University of Southampton

14.15 Stabilising Protein-Protein Interactions: A Challenge for Ligand Discovery
Dr Richard Doveston, University of Leicester
14.45 A novel crosslinking method allows rapid and unbiased analysis of dynamic and tight protein-protein interaction interfaces in vitro
Jim Horne, University of Leeds

15.00 Ligand directed fragment ligation targeting protein-protein interactions
Dr Zsófia Hegedüs, University of Leeds

15.15 Peptide grafting into a repeat-protein scaffold can impart low nanomolar affinity for Keap1
Sarah Madden, University of Cambridge

15.30 Stabilization of Protein-Protein Interactions
Dr Pim J. de Vink, Eindhoven University of Technology

15.45 Refreshments

16.00 A new method to probe protein interactions in solution
Dr Maya Wright, Fluidic

16.15 Plenary talk: Fragment Based Drug Discovery for PPIs
Dr David Rees, Astex Pharmaceuticals

17.00 Poster session and wine mixer

Friday 5 April

9.00 Plenary talk: Navigating the landscape of Bcl-2-binding peptides
Professor Amy Keating, Massachusetts Institute of Technology

9.45 A new class of RAS-effector protein-protein interaction inhibitors derived using an intracellular antibody fragment
Dr Philip Fallon, Domainex

10.15 Nanobodies directed against Tau protein to modulate its protein interactions in Alzheimer’s disease
Professor Isabelle Landrieu, Universite de Lille

10.45 Refreshments

11.15 Discovery of Mcl-1-specific inhibitor AZD5991 and structure based design learnings from Mcl-1 PPI inhibition
Dr Elisabetta Chiarparin, AstraZeneca

11.45 Getting in to deep water: the discovery and optimisation of BCL6 inhibitors 
Dr Ben Bellenie, ICR

12.15 Lunch, exhibition and posters

13.30 Development of a potent class of small molecule inhibitors of the MDM2-p53 protein-protein interaction
Dr Ian Hardcastle, University of Newcastle

14.00 Interaction of viral envelope proteins with host prohibitins
Dr Anja Winter, Keele University

14.30 The design and synthesis of selective CREBBP bromodomain ligands
Professor Stuart Conway, University of Oxford

15.00 Refreshments and poster prize presentation

15.15 Plenary talk: PROTAC-mediated Protein Degradation: A New Therapeutic Modality
Professor Craig Crews, Yale University

16.00 Closing remarks
16.15 Close

University of Leeds

University of Leeds, School of Chemistry, Woodhouse Lane, Leeds, LS2 9JT, United Kingdom

Organised by
Contact information
Showing all upcoming events
Start Date
End Date
Subject area
Event type


E-mail Enquiry